Renal manifestations and complications of inflammatory bowel disease
Corresponding Author
Konstantinos Oikonomou MD
Department of Gastroenterology
51, 31st August Street, 41221, Larissa, GreeceSearch for more papers by this authorTheodoros Eleftheriadis MD, PhD
Department of Nephrology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorIoannis Stefanidis MD, PhD
Department of Nephrology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorCorresponding Author
Konstantinos Oikonomou MD
Department of Gastroenterology
51, 31st August Street, 41221, Larissa, GreeceSearch for more papers by this authorTheodoros Eleftheriadis MD, PhD
Department of Nephrology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorIoannis Stefanidis MD, PhD
Department of Nephrology, University of Thessaly, School of Medicine, Larissa, Greece
Search for more papers by this authorAbstract
Renal manifestations and complications are not rare in patients with inflammatory bowel disease (IBD) and may present as nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis. Symptoms of renal impairment are not always specific and since the underlying bowel disease is preponderant, renal function deterioration may be underestimated. Additionally, medical treatment of patients with IBD such as aminosalicylates, cyclosporine, and tumor necrosis factor-α inhibitors can cause renal complications, although direct correlation to bowel disease is not always clear. The well-documented renal manifestations and complications of IBD, as well as the possible renal side effects of new drugs, emphasize the need for periodic evaluation of renal function. New markers of renal function may facilitate early diagnosis and unravel the complex mechanisms responsible for kidney damage. The purpose of this review is to summarize the renal manifestations and complications as well as the markers of renal function utilized in IBD, attempting to shed more light on the pathophysiology of renal damage in IBD. (Inflamm Bowel Dis 2011;)
REFERENCES
- 1 Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005; 14: 227–236.
- 2
Rothfuss KS,
Stange EF,
Herrlinger KR.
Extraintestinal manifestations and complications in inflammatory bowel diseases.
World J Gastroenterol.
2006;
14:
4819–4831.
10.3748/wjg.v12.i30.4819 Google Scholar
- 3 Pardi DS, Tremaine WJ, Sandborn WJ, et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol. 1998; 93: 504–514.
- 4 Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 63–68.
- 5 McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002; 89: 835–841.
- 6 Anderson H, Bosaeus I, Fasth S, et al. Cholelithiasis and urolithiasis in Crohn's disease. Scan J Gastroenterol. 1987; 22: 253–256.
- 7 Böhles H, Beifuss OJ, Brandl U, et al. Urinary factors of kidney stone formation in patients with Crohn's disease. Klin Wochenschr. 1988; 1: 87–91.
- 8 Parks JH, Worcester EM, O'Connor RC, et al. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003; 63: 255–265.
- 9 Kumar R, Ghoshal UC, Singh G, et al. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastroenterol Hepatol. 2004; 19: 1403–1409.
- 10 Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006; 101( 12 suppl ): S640–643.
- 11 Parmar MS. Kidney stones. BMJ. 2004; 12: 1420–1424
- 12 Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008; 35: 369–391.
- 13 Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009; 103: 18–21.
- 14 Nightingale J, Woodward JM. Guidelines for management of patients with a short bowel. Small Bowel and Nutrition Committee of the British Society of Gastroenterology. Gut. 2006; 55( suppl 4): iv1–12.
- 15 Nightingale JM. Management of patients with a short bowel. Nutrition. 1999; 15: 633–637.
- 16 Jonassen JA, Kohjimoto Y, Scheid CR, et al. Oxalate toxicity in renal cells. Urol Res. 2005; 33: 329–339.
- 17
Lindsjö M,
Fellström B,
Ljunghall S, et al.
Treatment of enteric hyperoxaluria with calcium-containing organic marine hydrocolloid.
Lancet.
1989;
23:
701–704.
10.1016/S0140-6736(89)90769-1 Google Scholar
- 18 Wharton R, D'Agati V, Magun AM, et al. Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol. 1990; 34: 116–121.
- 19 Efstratiadis G, Mainas A, Leontsini M. Renal amyloidosis complicating Crohn's disease. Case report and review of the literature. J Clin Gastroenterol. 1996; 22: 308–310.
- 20 Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001; 7: 295–300.
- 21 Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992; 71: 261–270.
- 22 Saitoh O, Kojima K, Teranishi T, et al. Renal amyloidosis as a late complication of Crohn's disease: a case report and review of the literature from Japan. World J Gastroenterol. 2000; 6: 461–464
- 23 Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008; 103: 776–787.
- 24 Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2001; 96: 2107–2112.
- 25 Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991; 70: 246–256.
- 26 Fernández-Nebro A, Ureña I, Irigoyen MV, et al. Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. Gut. 2006; 55: 1666–1667; author reply 1667.
- 27 Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn's disease treated with infliximab. Inflamm Bowel Dis. 2008; 14: 431–432
- 28 Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum. 2005; 52: 2519–2520.
- 29 Boscá MM, Pérez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut. 2006; 55: 294–295.
- 30 Iizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut. 2006; 55: 744–745.
- 31 Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13: 629–638.
- 32 Schreiber S, Hämling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997; 40: 761–766.
- 33 Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther. 2005; 15: 1217–1224.
- 34 Van Staa TP, Travis S, Leufkens HG, et al. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004; 126: 1733–1739.
- 35 Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14: 1–6.
- 36 Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002; 51: 536–539.
- 37 Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol. 2001; 32: 176–178.
- 38 Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992; 33: 1348–1352.
- 39 Fraser JS, Muller AF, Smith DJ, et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther. 2001; 15: 1131–1137.
- 40 Mahmud N, O'Toole D, O'Hare N, et al. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther. 2002; 16: 207–215.
- 41
Poulou AC,
Goumas KE,
Dandakis DC, et al.
Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?
World J Gastroenterol.
2006;
7;
12:
739–746.
10.3748/wjg.v12.i5.739 Google Scholar
- 42 Marcus SB, Brown JB, Melin-Aldana H, et al. Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr. 2008; 46: 338–341.
- 43 Izzedine H, Simon J, Piette AM, et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology. 2002; 123: 1436–1440.
- 44 Kreisel W, Wolf LM, Grotz W, et al. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996; 8: 461–468.
- 45 Herrlinger KR, Noftz MK, Fellermann K, et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther. 2001; 15: 363–369.
- 46 Mahmud N, McDonald GS, Kelleher D, et al. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut. 1996; 38: 99–103.
- 47 Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn's disease. BMJ. 1993; 28: 540–541.
- 48 Victorino RM, Lucas MB, de Moura MC. Severe osteomalacia associated with renal tubular acidosis in Crohn's disease. Dig Dis Sci. 1986; 31: 322–326.
- 49
Lok KH,
Hung HG,
Yip WM, et al.
Fulminant ulcerative colitis associated with steroid-resistant minimal change disease and psoriasis: a case report.
World J Gastroenterol.
2007;
7:
4022–4024.
10.3748/wjg.v13.i29.4022 Google Scholar
- 50 Peeters AJ, van den Wall Bake AW, Daha MR, et al. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis. 1990; 49: 638–640.
- 51 Iida H, Asaka M, Izumino K, et al. IgA nephropathy complicated by ulcerative colitis. Nephron. 1989; 53: 285–286.
- 52 Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol. 2002; 17: 863–866.
- 53 Onime A, Agaba EI, Sun Y, et al. Immunoglobulin A nephropathy complicating ulcerative colitis. Int Urol Nephrol. 2006; 38: 349–353.
- 54 Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis. 2005; 20: 463–465
- 55 Li KJ, Yu CL, Lin WC, et al. Concomitant aseptic subcutaneous abscess and immunoglobulin m nephropathy-rare extraintestinal manifestations in ulcerative colitis. Dig Dis Sci. 2006; 51: 401–405.
- 56 Casella G, Perego D, Baldini V, et al. A rare association between ulcerative colitis (UC), celiac disease (CD), membranous glomerulonephritis, leg venous thrombosis, and heterozygosity for factor V Leiden. J Gastroenterol. 2002; 37: 761–762.
- 57 Ridder RM, Kreth HW, Kiss E, et al. Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl. Pediatr Nephrol. 2005; 20: 1349–1351.
- 58 Shaer AJ, Stewart LR, Cheek DE, et al. IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis. 2003; 41: 1097–1099.
- 59 Schofield PM, Williams PS. Proliferative glomerulonephritis associated with Crohn's disease. Br Med J (Clin Res Ed). 1984; 20: 1039.
- 60 Presti ME, Neuschwander-Tetri BA, Vogler CA, et al. Sclerosing cholangitis, inflammatory bowel disease, and glomerulonephritis: a case report of a rare triad. Dig Dis Sci. 1997; 42: 813–816.
- 61 Ashman N, Sheaff M, Raftery MJ. Mesangiocapillary glomerulonephritis associated with ulcerative colitis: a 6-year follow-up of 2 cases. Clin Nephrol. 2003; 60: 146–148.
- 62 Fofi C, Nicoletti MC, Onetti Muda A, et al. Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis. G Ital Nefrol. 2003; 20: 641–644.
- 63 Molina-Pérez M, González-Reimers E, Santolaria-Fernández F, et al. Rapidly progressive glomerulonephritis and inflammatory bowel disease. Dis Colon Rectum. 1995; 38: 1006–1007.
- 64 Wilcox GM, Aretz HT, Roy MA, et al. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology. 1990; 98: 786–791.
- 65 Freedman BI, Spray BJ, Heise ER. HLA associations in IgA nephropathy and focal and segmental glomerulosclerosis. Am J Kidney Dis. 1994; 23: 352–357.
- 66 Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology. 1993; 104: 741–748.
- 67 De Jong DJ, Tielen J, Habraken CM, et al. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm Bowel Dis. 2005; 11: 972–976.
- 68 World MJ, Stevens PE, Ashton MA, et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11: 614–621.
- 69 Rhodes J, Coles GA. An alternative view of 5-ASA formulations. Gut. 1995; 36: 639–640.
- 70 Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicylic acid: 1993–1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996; 10: 949–956
- 71 Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine. BMJ. 1990; 6: 818
- 72 Thuluvath PJ, Ninkovic M, Calam J, et al. Mesalazine induced interstitial nephritis. Gut. 1994; 35: 1493–1496.
- 73 Wilcox GM, Reynolds JR, Galvanek EG. Nephrotoxicity associated with olsalazine. Am J Med. 1996; 100: 238–240.
- 74 Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut. 1992; 33: 1006–1007.
- 75 Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut. 1992; 33: 563–564.
- 76 Uslu N, Demir H, Saltik-Temizel IN, et al. Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci. 2007; 52: 2926–2929.
- 77 De Broe ME, Stolear JC, Nouwen EJ, et al. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant. 1997; 12: 1839–1841.
- 78
Popoola J,
Muller AF,
Pollock L, et al.
Late onset interstitial nephritis associated with mesalazine treatment.
BMJ.
1998;
19:
795–797.
10.1136/bmj.317.7161.795 Google Scholar
- 79 Tadic M, Grgurevic I, Scukanec-Spoljar M, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton). 2005; 10: 103–105.
- 80 Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther. 1996; 10: 941–947.
- 81
Sandborn WJ.
A critical review of cyclosporine therapy in inflammatory bowel disease.
Inflamm Bowel Dis.
1995;
1:
48–63.
10.1097/00054725-199503000-00006 Google Scholar
- 82 Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995; 109: 1001–1003.
- 83 Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 30: 1841–1845.
- 84 Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut. 2006; 55: 437–441.
- 85 Meijssen MA. Cyclosporine and inflammatory bowel disease: buying time. Mediators Inflamm. 1998; 7: 145–147.
- 86 McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005; 18: CD000297.
- 87 Stange EF, Modigliani R, Peña AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology. 1995; 109: 774–782.
- 88 Fellermann K, Lühmann D, Stange EF. Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. Inflamm Bowel Dis. 2003; 9: 198–201; discussion 202–204.
- 89 Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med. 1994; 30; 330: 1846–1851.
- 90 Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med. 1989; 28: 845–850.
- 91 Sandborn WJ, Tremaine WJ, Lawson GM. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol. 1996; 91: 37–43.
- 92 Bennett WM. Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Ren Fail. 1996; 18: 453–460.
- 93 Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int. 1996; 50: 1089–1100.
- 94 Bennett WM. The nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant. 1996; 11: 1899–1901.
- 95 Shang MH, Yuan WJ, Zhang SJ, et al. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin Med J (Engl). 2008; 5: 983–988.
- 96 Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up. Am J Gastroenterol. 2006; 101: 1048–1056.
- 97 Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008; 1: 589–597.
- 98 Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm Bowel Dis. 2007; 13: 769–796.
- 99 Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005; 15: 205–208.
- 100 Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum. 2009; 39: 176–181.
- 101 Thonhofer R, Soleiman A, Kriessmayr M, et al. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy. Scand J Rheumatol. 2006; 35: 485–488.
- 102 Verschueren P, Lensen F, Lerut E, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis. 2003; 62: 368–369.
- 103 Little MA, Bhangal G, Smyth CL, et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol. 2006; 17: 160–169.
- 104 Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol. 2007; 26: 1132–1133.
- 105 Den Broeder AA, Assmann KJ, van Riel PL, et al. Nephrotic syndrome as a complication of anti-TNF alpha in a patient with rheumatoid arthritis. Neth J Med. 2003; 61: 137–141.
- 106 Doulton TW, Tucker B, Reardon J, et al. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004; 62: 234–238.
- 107 Stokes M, Foster K, Markowitz G, et al. Development of glomerulonephritis during anti-TNF-therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005; 20: 1400–1406.
- 108 Chin G, Luxton G, Harvey J. Infliximab and nephritic syndrome. Nephrol Dial Transplant. 2005; 20: 2824–2826.
- 109 Kemp E, Nielsen H, Petersen LJ, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol. 2001; 55: 87–88.
- 110 Mor A, Bingham C 3rd, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005; 32: 740–743.
- 111 Haake H, Köneke J, Amann K, et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin (Munich). 2007; 15: 852–857.
- 112 Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. CRI (Club Rhumatismes et Inflammation). Joint Bone Spine. 2006; 73: 710–713.
- 113 Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86: 242–251.
- 114 Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000; 43: 2383–2390.
- 115 Ziolkowska M, Maslinski W. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol. 2003; 15: 267–273.
- 116 Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr Opin Nephrol Hypertens. 2006; 15: 610–616.
- 117 Trof RJ, Di Maggio F, Leemreis J, et al. Biomarkers of acute renal injury and renal failure. Shock. 2006; 26: 245–253.
- 118 Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008; 38: 32–46.
- 119 Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta. 2004; 16: 107–118.
- 120 Hong CY, Hughes K, Chia KS, et al. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003; 26: 338–342.
- 121 Bazzi C, Petrini C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002; 17: 1890–1896.
- 122 Miyata T, Jadoul M, Kurokawa K, et al. Beta-2 microglobulin in renal disease. J Am Soc Nephrol. 1998; 9: 1723–1735.
- 123 Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol. 2001; 96: 2177–2183.
- 124 Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 359–367.
- 125 Herrero-Morín JD, Málaga S, Fernández N, et al. Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children. Crit Care. 2007; 11: R59.
- 126 Hofstra JM, Deegens JK, Willems HL, et al. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol Dial Transplant. 2008; 23: 2546–2551.
- 127 Nitta K, Hayashi T, Uchida K, et al. Serum cystatin C concentration as a marker of glomerular filtration rate in patients with various renal diseases. Intern Med. 2002; 41: 931–935.
- 128 Herget-Rosenthal S, Bökenkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem. 2007; 40: 153–161.
- 129 Nakai K, Kikuchi M, Fujimoto K, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008; 12: 132–139.
- 130 Herget-Rosenthal S, van Wijk JA, Bröcker-Preuss M, et al. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem. 2007; 40: 946–951.
- 131 Monteleone et al. Altered IgG4 renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity. Nephrol Dial Transplant 2000: 15: 498–501.
- 132 Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am J Kidney Dis. 2008; 52: 395–399.
- 133 Zhou H, Pisitkun T, Aponte A, et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006; 70: 1847–1857.
- 134 Mehrotra R. Emerging role for fetuin-A as contributor to morbidity and mortality in chronic kidney disease. Kidney Int. 2007; 72: 137–140.